BAMEAO16B is a lipid nanoparticle. BAMEAO16B integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing. BAMEAO16B can be used for the research of gene editing. In Vitro BAMEA-O16B/Cas9 mRNA/sgHPV18 (HeLa cells) treatment significantly prohibits HeLa growth compared to that of a scramble sgRNA and Cas9 mRNA delivery. BAMEA-O16B shows RNA delivery efficiency. BAMEA-O16B shows mRNA encapsulation efficiency. BAMEA-O16B shows GFP knockout efficiency. BAMEA-O16B mediated Cas9mRNA delivery is able to regulate endogenous gene expression. BAMEA-O16B/RNA treated cells shows a higher endosome escape efficiency than that of BAMEA-O16/RNA treatment. BAMEA-O16B/RFP mRNA (HeLa cells) nanoparticles results in efficient RFP expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BAMEA-O16B/Cas9 mRNA/sgRNA (I.v.) nanoparticle effectively knocks mouse serum proprotein convertase subtilisin/kexin type 9 (PCSK9) level down to 20% of nontreated mouse. BAMEA-O16B/Cas9 mRNA/sgPCSK9 nanoparticle reduces mouse serum PCSK9 down to 20% of that with DPBS injection or BAMEA-O16B/Cas9 mRNA/scramblesgRNA nanoparticle injections . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Liquid